The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia
Open accessAbstract
Purpose: To conduct a phase I dose-escalation trial assessing safety and response of recombinant immunotoxin moxetumomab pasudotox (CAT-8015, HA22) in chemotherapy-resistant hairy cell leukemia (HCL). Patients and Methods: Eligible patients had relapsed/refractory HCL after ≥ two prior therapies and required treatment because of abnormal blood counts. Patients received moxetumomab pasudotox 5 to 50 μg/kg every other day for three doses (QOD ×3), with up to 16 cycles repeating at ≥ 4-week intervals if patients did not experience disease progression or develop neutralizing antibodies. Results: Twenty-eight patients were enrolled, including three patients each at 5, 10, 20, and 30 μg/kg, four patients at 40 μg/kg, and 12 patients at 50 μg/kg QOD ×3 for one to 16 cycles each (median, four cycles). Dose-limiting toxicity was not observed. Two patients had transient laboratory abnormalities consistent with grade 2 hemolytic uremic syndrome with peak creatinine of 1.53 to 1.66 mg/dL and platelet nadir of 106,000 to 120,000/μL. Drug-related toxicities in 25% to 64% of the 28 patients included (in decreasing frequency) grade 1 to 2 hypoalbuminemia, aminotransferase elevations, edema, headache, hypotension, nausea, and fatigue. Of 26 patients evaluable for immunogenicity, 10 patients (38%) made antibodies neutralizing more than 75% of the cytotoxicity of 1,000 ng/mL of immunotoxin, but this immunogenicity was rare (5%) after cycle 1. The overall response rate was 86%, with responses observed at all dose levels, and 13 patients (46%) achieved complete remission (CR). Only 1 CR lasted less than 1 year, with the median disease-free survival time not yet reached at 26 months. Conclusion: Moxetumomab pasudotox at doses up to 50 μg/kg QOD ×3 has activity in relapsed/refractory HCL and has a safety profile that supports further clinical development for treatment of this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755
Leukemic Reticuloendotheliosis
BOURONCLE, B. A., WISEMAN, B. K., & DOAN, C. A. (1958) · Blood · doi:10.1182/blood.v13.7.609.609 · Cited by 569
Kreitman, R. J., Wilson, W. H., White, J. D., Stetler-Stevenson, M., Jaffe, E. S., Giardina, S., Waldmann, T. A., & Pastan, I. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.8.1622 · Cited by 420
Self-citationHassan, R., Bullock, S., Premkumar, A., Kreitman, R. J., Kindler, H., Willingham, M. C., & Pastan, I. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0869 · Cited by 379
Self-citationLong-Term Follow-Up of Patients With Hairy Cell Leukemia After Cladribine Treatment
Saven, A., Burian, C., Koziol, J. A., & Piro, L. D. (1998) · Blood · doi:10.1182/blood.v92.6.1918 · Cited by 329
Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P
Kreitman, R. J., Hassan, R., FitzGerald, D. J., & Pastan, I. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0062 · Cited by 222
Self-citationSeymour, J., Kurzrock, R., Freireich, E., & Estey, E. (1994) · Blood · doi:10.1182/blood.v83.10.2906.2906 · Cited by 207
Salvatore, G., Beers, R., Margulies, I., Kreitman, R. J., & Pastan, I. H. (2002) · PubMed · Cited by 153
Self-citationAlderson, R. F., Kreitman, R. J., Chen, T., Yeung, P., Herbst, R., Fox, J. A., & Pastan, I. H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1456 · Cited by 104
Self-citationThrombotic Microangiopathy with Targeted Cancer Agents
Blake-Haskins, J. A., Lechleider, R. J., & Kreitman, R. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0804 · Cited by 92
Self-citation
Cited by
Fry, T. J., Shah, N. N., Orentas, R. J., Stetler-Stevenson, M., Yuan, C. M., Ramakrishna, S., Wolters, P., Martin, S., Delbrook, C., Yates, B., et al. (2018) · Nature Medicine · doi:10.1038/nm.4441 · Cited by 1,335
Self-citationAntibody–drug conjugates for cancer therapy
Thomas, A., Teicher, B. A., & Hassan, R. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30030-4 · Cited by 606
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia
Grever, M. R., Abdel-Wahab, O., Andritsos, L. A., Banerji, V., Barrientos, J., Blachly, J. S., Call, T. G., Catovsky, D., Dearden, C., Demeter, J., et al. (2017) · Blood · doi:10.1182/blood-2016-01-689422 · Cited by 289
Self-citation
Metadata
- Authors
- Kreitman, R. J., Tallman, M. S., Robak, T., Coutre, S., Wilson, W. H., Stetler-Stevenson, M., FitzGerald, D. J., Lechleider, R., & Pastan, I.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-05-20
- Volume
- 30
- Issue
- 15
- Pages
- 1822-1828
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2156671071
- Cited by
- 295
- References
- 10
- FWCI
- 18.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia. https://app.cochat.ai/papers/10.1200/jco.2011.38.1756
- The paper
- Kreitman, R. J., Tallman, M. S., Robak, T., Coutre, S., Wilson, W. H., Stetler-Stevenson, M., FitzGerald, D. J., Lechleider, R., & Pastan, I. (2012). Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2011.38.1756
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.